In 2018 the USPSTF did an about-face once again on PSA screening, reversing its 2012 recommendation against it. This cross-sectional study of CDC data on the 618,095 men dying of prostate cancer between 1999-2019 in the US detected a steady decline in prostate cancer mortality from 1999-2012 after which mortality rates began to stagnate. This dip followed by a plateau was seen across all demographics, supporting the current guidelines to discuss PSA screening with all men ages 55-69. | Burgess, JAMA Netw Open 2022


Popular Posts